St. Anton, Austria January 19-23, 2020
Registration
Opening Remarks
Necessity is the Mother of Invention: Natural Products and the Chemistry They Inspire (KL01)
Prof. Sarah E. REISMAN
CALIFORNIA INSTITUTE OF TECHNOLOGY, Pasadena, United States
Poster Session & Welcome Reception
End of Day 1
Session Chair
Dr Amit KALGUTKAR
PFIZER, Groton, United States
Structural Attributes Influencing Unbound Tissue Distribution (PL01)
Dr Li DI
PFIZER, Groton, United States
Metabolism of Strained Rings: Tales of the Unexpected (PL02)
Dr Martin HAYES
ASTRAZENECA, Gothenburg, Sweden
Coffee Break
Leveraging In Silico ADMET Profiles and Ancillary Pharmacology to Influence Prioritization of Hit Series with Higher Probability of Success (PL03)
Dr Falgun SHAH
MERCK & CO., West Point, United States
Predicting ADME - Reality, Vision or Fantasy? (PL04)
Dr Simone SCHADT
F. HOFFMANN-LA ROCHE, Basel, Switzerland
Outdoor Networking Activities
Networking Break
NovAliX Workshop: DNA-Encoded Libraries, an Integrated Platform for Hit Finding and Beyond
Dr Julien MARIN
NOVALIX, Illkirch, France
Session Chair
Prof. Sarah E. REISMAN
CALIFORNIA INSTITUTE OF TECHNOLOGY, Pasadena, United States
Break-it-to-Make-it Strategies for Complex Molecule Synthesis (PL05)
Prof. Richmond SARPONG
UNIVERSITY OF CALIFORNIA, BERKELEY, Berkeley, United States
New Avenues in Synthesis Enabled by Organic Photoredox Catalysis (PL06)
Prof. David NICEWICZ
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, Chapel Hill, United States
Coffee Break
Late-Stage Functionalizations (PL07)
Prof. Tobias RITTER
MAX-PLANCK-INSTITUT FÜR KOHLENFORSCHUNG, Mulheim, Germany
A Radical Way to Abeo-Steroids (PL08)
Prof. Philipp HERETSCH
FREE UNIVERSITY OF BERLIN, Berlin, Germany
Poster Session
End of Poster Session
Conference Dinner
End of Day 2
Membrane Proteins at the SGC – Challenges and Success Stories (PL09)
Dr Katharina DUERR
UNIVERSITY OF OXFORD, Oxford, United Kingdom
The Mechanism of Outer Membrane Protein Insertion by BamA and its Role as a Target for Novel Antibiotic (PL10)
Prof. Sebastian HILLER
UNIVERSITY OF BASEL, Basel, Switzerland
Coffee Break
Discovery of ABL001, an Allosteric Inhibitor of BCR-ABL: Fragments, Biophysics, Structure and Chemistry (PL11)
Dr Wolfgang JAHNKE
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland
Discovery of Small Molecule Fascin 1 Inhibitors Using Fragment-Based Drug Discovery (OC01)
Dr Stuart FRANCIS
THE BEATSON INSTITUTE FOR CANCER RESEARCH, Glasgow, United Kingdom
Outdoor Networking Activities
Networking Break & "Beyond-the-Science Leadership Development" Workshop
Session Chair
Dr Michelle CLAFFEY
CLAFFEY LEADERSHIP, Norwich, United States
Session Chair
Session Chair
Prof. Alessio CIULLI
UNIVERSITY OF DUNDEE, Dundee, United Kingdom
Chemical Genomics Approaches to Targeted Protein Degradation (PL13)
Dr Georg WINTER
RESEARCH CENTER FOR MOLECULAR MEDICINE OF THE AUSTRIAN ACADEMY OF SCIENCES, Vienna, Austria
Four E3 Ligases, One Target: Towards Novel CDK6 Protacs (OC02)
Dr Christian STEINEBACH
UNIVERSITY OF BONN, Bonn, Germany
Coffee Break
Expanding the Druggable Genome through Cereblon-Mediated Protein Degradation (KL02)
Dr Lawrence G. HAMANN
BRISTOL-MYERS SQUIBB, Cambridge, United States
End of Day 3
Session Chair
Prof. Thomas MAGAUER
UNIVERSITY OF INNSBRUCK, Innsbruck, Austria
Capturing Biological Activity in Natural Product Fragments: Success and Limitations (PL14)
Prof. Karl GADEMANN
UNIVERSITY OF ZÜRICH, Zürich, Switzerland
(De)Construction of Three-Dimensional Molecular Architectures (PL15)
Prof. Thomas MAGAUER
UNIVERSITY OF INNSBRUCK, Innsbruck, Austria
Coffee Break
Synthesis of Complex Antiplasmodial Isocyanoterpenes (PL16)
Prof. Christopher VANDERWAL
UNIVERSITY OF CALIFORNIA, Irvine, United States
Outdoor Networking Activities
Networking Break & "Panel Discussion on Protein Degradation"
Session Chair
Dr Klemens HOEGENAUER
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland
Prof. Alessio CIULLI
UNIVERSITY OF DUNDEE, Dundee, United Kingdom
Dr Georg WINTER
RESEARCH CENTER FOR MOLECULAR MEDICINE OF THE AUSTRIAN ACADEMY OF SCIENCES, Vienna, Austria
Session Chair
Dr Thomas TRIESELMANN
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach an der Riss, Germany
Organic Synthesis on a Computer: Should Medicinal Chemists Care? (PL17)
Prof. Bartosz A. GRZYBOWSKI
ULSAN NATIONAL INSTITUTE OF SCIENCE & TECHNOLOGY, Ulsan, Korea, South
Exploring an Interface of Synthesis and Data Science (PL18)
Prof. Timothy CERNAK
UNIVERSITY OF MICHIGAN, Ann Arbor, United States
Accelerating R&D with Augmented Intelligence (PL19)
Dr Matthias ZENTGRAF
BOEHRINGER INGELHEIM, Biberach an der Riss, Germany
Coffee Break
Session Chair
Dr Philippe NANTERMET
MERCK & CO. INC (MSD), West Point, United States
Using Small Molecules to Engineer and Explore Human Immunity (PL20)
Prof. David SPIEGEL
YALE UNIVERSITY, New Haven, United States
Poster Session
End of Day 4
Session Chair
Dr Philippe NANTERMET
MERCK & CO. INC (MSD), West Point, United States
Discovery of Tumor-Targeted TLR7/8 Immune-Stimulating Antibody Conjugates (ISAC): A New Class of Immuno-Oncology Therapeutics (PL21)
Dr Brian SAFINA
BOLT BIOTHERAPEUTICS, Redwood City, United States
Intracellular and Tissue Specific Targeting of Therapeutic Modalities (PL22)
Dr Vadim DUDKIN
JANSSEN DISCOVERY SCIENCES, Lansdale, United States
Coffee Break
SBT6050, a HER2-Directed TLR8 Immunotac™ Therapeutic, is a Potent Human Myeloid Cell Agonist with Tumor-Localized Activity (PL23)
Dr Valerie ODEGARD
SILVERBACK THERAPEUTICS, Seattle, United States
Outdoor Networking Activities
Networking Break
Session Chair
Dr Lena RIPA
ASTRAZENECA, Sweden
Discovery of GDC-0334: a potent and orally bioavailable clinical candidate for the inhibition of TRPA1 (OC04)
Dr Vishal VERMA
GENENTECH, South San Francisco, United States
Investigating the Chameleonic Properties of RGD Integrin Antagonists for the Treatment of IPF (OC05)
Dr James THOMPSON
GLAXOSMITHKLINE/UNIVERSITY OF STRATHCLYDE, Stevenage, United Kingdom
Discovery of AZD3458 a Highly Selective PI3Ky Inhibitor: Combining Structure, HDX-MS and Binding Kinetics to Understand the Mode of Action (OC06)
Dr Nils PEMBERTON
ASTRAZENECA, Mölndal, Sweden
The Discovery of a Potent and Orally Bioavailable Macrocyclic Cyclophilin Inhibitor Based on The Structural Simplification of Sanglifehrin A (OC07)
Dr Vicky STEADMAN
EUROFINS DISCOVERY, Essex, United Kingdom
Coffee Break
The Big Impact of Small Changes : Towards Best-in-Class EZH2 and LSD1 Inhibitors (OC08)
Dr Julian LEVELL
CONSTELLATION PHARMACEUTICALS, Cambridge, United States
Controlling the Fate and Function of Proteins with Photopharmacology (KL03)
Prof. Dirk TRAUNER
NEW YORK UNIVERSITY, New York, United States
Closing Remarks
End of Symposium